MACRO Trial
The main MACRO trial found ESS significantly better than clarithromycin or placebo at 6 months on patient-reported SNOT-22 scores. The MACRO trial compared endoscopic sinus surgery, clarithromycin, and placebo in patients with chronic rhin…
1 sources - 5 claims
The main MACRO trial found ESS significantly better than clarithromycin or placebo at 6 months on patient-reported SNOT-22 scores. The MACRO trial compared endoscopic sinus surgery, clarithromycin, and placebo in patients with chronic rhinosinusitis with and without nasal polyps. Clarithromycin did not show significant benefit over placebo in the MACRO trial.